These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 9191951)

  • 1. 9-Benzyladenines: potent and selective cAMP phosphodiesterase inhibitors.
    Bourguignon JJ; Désaubry L; Raboisson P; Wermuth CG; Lugnier C
    J Med Chem; 1997 Jun; 40(12):1768-70. PubMed ID: 9191951
    [No Abstract]   [Full Text] [Related]  

  • 2. 8-Substituted analogues of 3-(3-cyclopentyloxy-4-methoxy-benzyl)-8-isopropyl-adenine: highly potent and selective PDE4 inhibitors.
    Whitehead JW; Lee GP; Gharagozloo P; Hofer P; Gehrig A; Wintergerst P; Smyth D; McCoull W; Hachicha M; Patel A; Kyle DJ
    J Med Chem; 2005 Feb; 48(4):1237-43. PubMed ID: 15715490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of purine inhibitors of phosphodiesterase 7 (PDE7).
    Pitts WJ; Vaccaro W; Huynh T; Leftheris K; Roberge JY; Barbosa J; Guo J; Brown B; Watson A; Donaldson K; Starling GC; Kiener PA; Poss MA; Dodd JH; Barrish JC
    Bioorg Med Chem Lett; 2004 Jun; 14(11):2955-8. PubMed ID: 15125967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does sildenafil indirectly inhibit phosphodiesterase 3 in vascular smooth muscle?
    Maurice DH
    Hypertension; 2003 Mar; 41(3):e2. PubMed ID: 12623968
    [No Abstract]   [Full Text] [Related]  

  • 5. Selective inhibitors of cyclic AMP-specific phosphodiesterase: heterocycle-condensed purines.
    Sawanishi H; Suzuki H; Yamamoto S; Waki Y; Kasugai S; Ohya K; Suzuki N; Miyamoto K; Takagi K
    J Med Chem; 1997 Sep; 40(20):3248-53. PubMed ID: 9379444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphodiesterase 4 isoenzyme inhibitory activity of 3-phenylxanthines and 4-pheny.
    Suzuki H; Sawanishi H; Yamamoto K; Yokogawa K; Miyamoto K
    Chem Pharm Bull (Tokyo); 2001 Feb; 49(2):188-91. PubMed ID: 11217107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 1: design, synthesis and structure-activity relationship studies.
    Vergne F; Bernardelli P; Lorthiois E; Pham N; Proust E; Oliveira C; Mafroud AK; Royer F; Wrigglesworth R; Schellhaas J; Barvian M; Moreau F; Idrissi M; Tertre A; Bertin B; Coupe M; Berna P; Soulard P
    Bioorg Med Chem Lett; 2004 Sep; 14(18):4607-13. PubMed ID: 15324874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of cyclic GMP-inhibited phosphodiesterases 3A and 3B (PDE3A and PDE3B) in rat tissues: differential subcellular localization and regulated expression by cyclic AMP.
    Liu H; Maurice DH
    Br J Pharmacol; 1998 Dec; 125(7):1501-10. PubMed ID: 9884079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and structure-activity relationships of guanine analogues as phosphodiesterase 7 (PDE7) inhibitors.
    Barnes MJ; Cooper N; Davenport RJ; Dyke HJ; Galleway FP; Galvin FC; Gowers L; Haughan AF; Lowe C; Meissner JW; Montana JG; Morgan T; Picken CL; Watson RJ
    Bioorg Med Chem Lett; 2001 Apr; 11(8):1081-3. PubMed ID: 11327595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of the effects of phosphodiesterase type 3 and 4 inhibitors in cerebral arteries.
    Birk S; Edvinsson L; Olesen J; Kruuse C
    Eur J Pharmacol; 2004 Apr; 489(1-2):93-100. PubMed ID: 15063160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclic AMP phosphodiesterase 4 isoenzyme inhibitory activity of (R)- and (S)-isomer of 7-methyl- or 8-alkyl-4,5,7,8-tetrahydroimidazo[2,1-i]- purin-5-one.
    Suzuki H; Nomura M; Miyamoto K; Sawanishi H; Yamamoto K
    Biol Pharm Bull; 2004 Mar; 27(3):357-60. PubMed ID: 14993802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spiroquinazolinones as novel, potent, and selective PDE7 inhibitors. Part 1.
    Lorthiois E; Bernardelli P; Vergne F; Oliveira C; Mafroud AK; Proust E; Heuze L; Moreau F; Idrissi M; Tertre A; Bertin B; Coupe M; Wrigglesworth R; Descours A; Soulard P; Berna P
    Bioorg Med Chem Lett; 2004 Sep; 14(18):4623-6. PubMed ID: 15324876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2,1,3-Benzothiadiazine derivatives: synthesis and screening versus PDE4 enzyme.
    Tait A; Luppi A; Avallone R; Baraldi M
    Farmaco; 2005 Aug; 60(8):653-63. PubMed ID: 15963514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclic nucleotide-mediated regulation of vascular smooth muscle cell cyclic nucleotide phosphodiesterase activity. Selective effect of cyclic AMP.
    Maurice DH
    Cell Biochem Biophys; 1998; 29(1-2):35-47. PubMed ID: 9631237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition by 2- or/and 8-substituted adenosine derivatives of adenosine deaminase and calmodulin-dependent phosphodiesterase.
    Sasaki Y; Ono Y
    Nucleic Acids Symp Ser; 1980; (8):s163-6. PubMed ID: 6265879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential regulation of human platelet responses by cGMP inhibited and stimulated cAMP phosphodiesterases.
    Manns JM; Brenna KJ; Colman RW; Sheth SB
    Thromb Haemost; 2002 May; 87(5):873-9. PubMed ID: 12038792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First dual M3 antagonists-PDE4 inhibitors: synthesis and SAR of 4,6-diaminopyrimidine derivatives.
    Provins L; Christophe B; Danhaive P; Dulieu J; Durieu V; Gillard M; Lebon F; Lengelé S; Quéré L; van Keulen B
    Bioorg Med Chem Lett; 2006 Apr; 16(7):1834-9. PubMed ID: 16439121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enaminones 9. Further studies on the anticonvulsant activity and potential type IV phosphodiesterase inhibitory activity of substituted vinylic benzamides.
    Anderson AJ; Nicholson JM; Bakare O; Butcher RJ; Wilson TL; Scott KR
    Bioorg Med Chem; 2006 Feb; 14(4):997-1006. PubMed ID: 16219468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 2: metabolism-directed optimization studies towards orally bioavailable derivatives.
    Vergne F; Bernardelli P; Lorthiois E; Pham N; Proust E; Oliveira C; Mafroud AK; Ducrot P; Wrigglesworth R; Berlioz-Seux F; Coleon F; Chevalier E; Moreau F; Idrissi M; Tertre A; Descours A; Berna P; Li M
    Bioorg Med Chem Lett; 2004 Sep; 14(18):4615-21. PubMed ID: 15324875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spiroquinazolinones as novel, potent, and selective PDE7 inhibitors. Part 2: Optimization of 5,8-disubstituted derivatives.
    Bernardelli P; Lorthiois E; Vergne F; Oliveira C; Mafroud AK; Proust E; Pham N; Ducrot P; Moreau F; Idrissi M; Tertre A; Bertin B; Coupe M; Chevalier E; Descours A; Berlioz-Seux F; Berna P; Li M
    Bioorg Med Chem Lett; 2004 Sep; 14(18):4627-31. PubMed ID: 15324877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.